Print
Email
Print Edition StoriesMonday, December 7, 2009
Immunogen returns positive results in Phase 1 cancer therapy trial
By Craig M. Douglas
Funding drugs for rare diseases
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
Drug developer Immunogen Inc. said preliminary Phase 1 testing for its BT-062 cancer therapy has produced “encouraging” results that merit a new round of trials featuring a more frequent dosing regimen. The treatment is intended for patients with relapsed and relapsed/refractory multiple myeloma.
The results were presented Saturday at the American Society of Hematology’s annual meeting in New Orleans.
The drug is comprised of Waltham-based Immunogen’s DM4 cancer-cell killing agent and an antibody developed by Germany’s Biotest AG. The two companies are developing the BT-062 drug target via a collaboration agreement inked earlier this year.
The 25-patient trial’s objective was to identify maximum-tolerated dosages, dose-limiting toxicities and clinical efficacy, according to a regulatory filing.
Patients in the trial received one of seven dosage levels and had been previously treated with a median of seven other cancer therapies.
Immunogen (Nasdaq: IMGN) called the toxicity results “acceptable,” adding that just over half of the 17 patients who received more than one treatment cycle experienced delayed progression in their cancer.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
